Therapeutic effect improvement by new boron neutron capture therapy with amino acid - BSH

新型氨基酸硼中子俘获疗法改善疗效 - BSH

• 批准号: 23592146
• 负责人: KAWABATA Shinji
• 金额: $ 3.41万
• 依托单位: Osaka Medical College
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23592146/
• 关键词: 脳腫瘍学; 悪性神経膠腫; 放射線治療; ホウ素化合物; 中性子捕捉療法; 合成アミノ酸; ドラッグデリバリーシステム

Boron neutron capture therapy (BNCT) is based on the nuclear capture and fission reactions that occur when non-radioactive Boron-10 is irradiated with low energy thermal neutrons to produce alpha- particles inside one cell level. The L-amino acid transport system in tumor cells is enhanced compared with normal cells. We designed, synthesized and tested boron carrying unnatural amino-acid, ACBC-BSH, as boron drug for BNCT. Curative effect of ACBC-BSH groups was approximately equal to BPA. The reason is that we think that extracellular accumulations of ACBC-BSH indicating that the seemingly high tumor boron concentrations did not represent the true tumor cellular uptake. And we did not compete for the curative effect by using ACBC-BSH together in BPA and accepted meaningful duration of survival time. Difference in drug distribution at the cell level was regarded as the cause. This study suggested the possibility that ACBC-BSH became the drug to add curative effect to.

硼中子俘获疗法（BNCT）是基于低能量热中子照射非放射性硼-10以产生细胞内α -粒子时发生的核俘获和裂变反应。与正常细胞相比，肿瘤细胞中的l -氨基酸转运系统增强。我们设计、合成并测试了携带非天然氨基酸的硼ACBC-BSH作为BNCT的硼药。ACBC-BSH组与BPA组疗效相近。原因是我们认为ACBC-BSH的细胞外积累表明看似高的肿瘤硼浓度并不能代表真正的肿瘤细胞摄取。在双酚a中同时使用ACBC-BSH不竞争疗效，并接受有意义的生存时间。细胞水平药物分布的差异被认为是原因。本研究提示ACBC-BSH成为增效药物的可能性。

项目成果

悪性神経膠腫の放射線治療後再発例に対するホウ素中性子捕捉療法の成績

硼中子俘获疗法治疗恶性胶质瘤放疗后复发的结果

• 发表时间: 2014
• 期刊: 定位放射線治療
• 作者: 川端信司;平松亮;古瀬元雅;松下葉子;二村元;大西宏之;黒岩敏彦;近藤夏子;鈴木実;櫻井良憲;田中浩基;小野公二;宮武伸一
• 通讯作者: 宮武伸一